Results of study showing brentuximab vedotin was an effective therapy for relapsed hodgkin prior to autologous stem cell transplant.
Home / Resource Library / Brentuximab Vedotin in Transplant-Naive Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients